FDA has announced that it is amending the general biologics regulations regarding inspection timing and inspector requirements (21 CFR 600.21 and 21 CFR 600.22). The intention is to remove outdated requirements and accommodate new approaches, such as a risk-based inspection frequency for drug establishments.
INTERNATIONAL PHARMACEUTICAL QUALITY
Inside the Global Regulatory Dialogue
